LIQUIDIA CORPORATION Accounts Payable
LIQUIDIA CORPORATION (LQDA) had Accounts Payable of $12.75 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-12
- 2026-06-30: Accounts Payable, Current $12.75M.
- 2026-03-31: Accounts Payable, Current $10.98M.
- 2025-12-31: Accounts Payable, Current $3.68M.
- 2025-09-30: Accounts Payable, Current $6.02M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $12.75M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $10.98M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $3.68M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $6.02M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $11.35M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $8.68M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $4.69M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $2.30M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $5.74M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $2.49M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $1.40M 8-K · filed 2025-05-08 | |
| 2023-09-30 | $1.81M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $1.92M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $841.00K 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $2.20M 10-K · filed 2024-03-13 | |
| 2022-09-30 | $1.14M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $1.41M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $1.67M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $1.07M 10-K · filed 2023-03-20 | $1.07M 10-K · filed 2022-03-17 |
| 2021-09-30 | $1.61M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $2.55M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $3.00M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $3.73M 10-K · filed 2022-03-17 | |
| 2019-12-31 | $3.50M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |